Global Levonorgestrel API Market Overview:
Levonorgestrel API is a hormonal medication used in birth control medicines. It is combined with an estrogen to make combination birth control pills. It is useful within 120 hours as emergency birth control. Levonorgestrel API tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. The growing demand for the birth control pills has driven the market size.
Growth Drivers
- Rising Demand For Birth Control Pills Worldwide
- Increasing Investment In Pharmaceutical Development
Roadblocks
- Risk Of Side Effects Such As Irregular Bleeding, Nausea, Abdominal Pain, Vomiting Etc.
Opportunities
- Ease Availability Of Levonorgestrel API In Emerging Countries
- Prospective Trials Of Levonorgestrel As Emergency Contraception
Challenges
- Availability Of Counterfeit Drugs
Competitive Landscape:
The global levonorgestrel API market is fragmented by numerous key players who have the bargaining power high in this market as there are many regional manufacturers. Despite the presence of competition and brand effect problems, due to the awareness of end-users and demand for levonorgestrel based products, the investors are still optimistic about this area. There will be more new investors entering into this industry in the future.
Some of the key players profiled in the report are ScinoPharm (Taiwan), 3M Drug Delivery Systems (United States), Bayer AG (Germany), Cipla (India), Gedeon Richter (Hungary), Hangzhou Longshine Bio-Tec (China), Hubei Gedian Humanwell Pharmaceutical, Indo Phyto Chemicals (India), Industriale Chimica (Italy), Jenapharm (Germany), Lupin Limited (India), Naari AG (Switzerland), Qinhuangdao Zizhu Pharmaceutical (China), Sterling Chemical Malta Ltd (Malta), Symbiotec Pharmalab Private Limited (India) and Yangzhou Pharmaceutical (China). Considering Market by Drugs Type, the sub-segment i.e. Prescription Drugs will boost the Levonorgestrel API market. Considering Market by Grade, the sub-segment i.e. BP (British Pharmacopoeia) will boost the Levonorgestrel API market.
Latest Market Insights:
On 4th May 2020, ScinoPharm’s Transformation Continues to Yield Results Stable Development in Injection Business.ScinoPharm’s Transformation Continues to Yield Results Stable Development in Injection Business
What Can be Explored with the Levonorgestrel API Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Levonorgestrel API Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Levonorgestrel API
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Levonorgestrel API market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Levonorgestrel API market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Levonorgestrel API Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.